- September 13, 2024
- July 28, 2024
- June 12, 2024
- June 12, 2024Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the…
- June 11, 2024In the past 5 years, we have witnessed the first approved Alzheimer disease (AD) disease-modifying therapy and the development of…
- February 22, 2024In this study involving Chinese participants during the 20 years preceding clinical diagnosis of sporadic Alzheimer’s disease, we observed the…
- February 21, 2024
- June 8, 2023Herein, we review data on BBBMs that are closest to clinical implementation, particularly those based on measures of amyloid-β peptides…
- July 31, 2022Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well…
- May 26, 2022Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both amyloid and tau pathology in clinical settings, but…